Baird Downgrades Regeneron Pharma (REGN) to Neutral

(updating comment)

Baird analyst Brian Skorney downgraded Regeneron Pharma (NASDAQ: REGN) from Outperform to Neutral with a price target of $410.00.

The analyst comments "Although we certainly appreciate the tailwind granted by safety concerns related to Eylea competitor, Beovu, we would rather take the 50% bump to the stock since our August 2019 upgrade than join the crusade of analysts now calling for REGN outperformance. While the fall of Beovu certainly relieves nearterm pressure on Eylea market share, we think this has now been accounted for in the share price and are downgrading to Neutral."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $442.35 yesterday.

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald